Galera Therapeutics Announces 1:200 Reverse Stock Split Effective July 12

summarizeSummary

Galera Therapeutics announced its board approved a 1-for-200 reverse stock split, effective July 12, 2026, a critical step following shareholder approval and amidst its merger with Obsidian Therapeutics.

check_boxKey Events · Corporate Governance and Compliance · GRTX

• Board Approves 1:200 Reverse Stock Split

  The board of directors approved a one-for-two hundred (1:200) reverse stock split of the company's common stock.

• Effective Date Set for July 12, 2026

  The reverse stock split is expected to become effective on July 12, 2026, with split-adjusted shares beginning to trade on July 13, 2026.

• Fractional Shares to Receive Cash

  No fractional shares will be issued; stockholders will receive cash value for any fractional shares based on the closing price prior to the effective date.

• Equity Plans and Warrants Adjusted

  The reverse split will proportionally adjust shares available under equity incentive plans and shares issuable upon exercise of outstanding stock options and warrants, with corresponding changes to exercise prices.

auto_awesomeAnalysis · GRTX · Life Sciences

This 8-K finalizes the terms and effective date for a highly aggressive 1-for-200 reverse stock split, a move previously approved by shareholders. While reverse splits do not change a company's fundamental value, this action is often a precursor to meeting exchange listing requirements or improving stock perception, especially for a company facing a going concern warning and undergoing a highly dilutive merger. The extreme ratio reflects the company's very low share price and the challenges it faces.